CapsoVision Q3 2026 Results: Net Loss of $7.34M, Loss Narrows
CapsoVision reported a net revenue of $10.0 million for the nine months ended September 30, 2026, a slight increase from $9.6 million in the prior year. However, the company experienced a net loss of $21.9 million during this period, driven by high research and development expenses as they pursue FDA clearances for new products like the CapsoCam Colon capsule and AI capabilities.
- Key figure
- Net loss $7.34M